This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools for extrapolating in vitro and animal study data to humans.
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully transition investigational drugs from research to a commercially profitable product. These companies need to secure a combination of sophisticated investors, partners, and expert consultants to...
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully transition investigational drugs from research to a commercially profitable product. These companies need to secure a combination of sophisticated investors, partners, and expert consultants to...
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully transition investigational drugs from research to a commercially profitable product. These companies need to secure a combination of sophisticated investors, partners, and expert consultants to...
This blog explains how using the Gene Therapy Virtual Twin™ Platform can help optimize dosing for patients
Streamlines drug development by using PBPK modeling to predict drug behavior in virtual populations, optimize clinical study design, assess drug-drug interactions, and support regulatory decisions.
Certara’s Simcyp® Biologics platform enables scientists to model and predict the pharmacokinetics and pharmacodynamics of biologics, enhancing drug development and safety assessments.
This blog provides 8 clinical pharmacology and pharmacokinetic considerations that you should know for oligonucleotide therapeutics.
Expertly written patient narratives, enhanced by CoAuthor, ensuring consistency, quality, and improving safety reporting.
© 2025 Certara. All Rights Reserved. | Privacy policy
